Making the Best Use of Available Weapons for the Inevitable Rivalry-Resistance to EGFR-TKIs

Area of Science:

• Oncology
• Pharmacology
• Genetics

Background:

• Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) transformed advanced non-small cell lung cancer (NSCLC) treatment.
• EGFR mutations are common in Asian patients with lung adenocarcinoma, historically considered a targetable marker.
• Acquired resistance to EGFR-TKIs, including third-generation agents, remains a significant clinical challenge.

Purpose of the Study:

• To review the clinical efficacy of third-generation EGFR-TKIs in EGFR-mutated NSCLC.
• To discuss strategies for sequential treatment to overcome or delay TKI resistance.
• To elucidate resistance mechanisms and propose future therapeutic approaches.

Main Methods:

• Literature review of clinical evidence on third-generation EGFR-TKIs.
• Analysis of resistance mechanisms in EGFR-mutated NSCLC.
• Exploration of novel therapeutic strategies, including antibody drug conjugates.

Main Results:

• Third-generation EGFR-TKIs demonstrate effectiveness in managing certain resistance mutations like T790M.
• Sequential treatment strategies show promise in prolonging patient benefit.
• Understanding resistance mechanisms is crucial for developing next-generation therapies.

Conclusions:

• Despite advancements, resistance to third-generation EGFR-TKIs necessitates ongoing research.
• Novel strategies, including antibody drug conjugates and adaptive treatment, are vital for managing NSCLC.
• Future research should focus on shaping tumor evolution for sustained therapeutic response.